26th week of 2010 patent applcation highlights part 56 |
Patent application number | Title | Published |
20100167964 | Compositions and Methods for Treating a Water Blocked Well - The present invention includes a method of treating a hydrocarbon-bearing clastic formation having non-connate water by contacting the hydrocarbon-bearing clastic formation with a composition that includes a solvent and a nonionic fluorinated polymeric surfactant wherein the solvent at least partially displaces or solubilizes the water in the formation. | 2010-07-01 |
20100167965 | Amphiphobic Proppant - Methods and compositions for forming a hydraulic fracture are disclosed herein. The methods and compositions make use of novel amphiphobic proppants. The amphiphobic properties of the disclosed proppant compositions provide several advantages over existing solutions. The hydrophobic nature of the proppant enhances recovery of fracture fluid from the fracture as well as prevents liquid build-up with the fracture. Additionally, the lipophobic nature of the proppant may enhance production of hydrocarbons from the fracture. | 2010-07-01 |
20100167966 | CORROSION INHIBITORS - Provided is an anticorrosive composition for use in aqueous salt solutions. The composition contains an antimony compound and at least two other components selected from morpholine derivatives, acetylenic alcohols, ascorbic acid derivatives, and selenium compounds. The composition is particularly useful for inhibiting corrosion of metallic surfaces of drilling devices or refrigeration systems that are in contact with salt brines at elevated temperatures. | 2010-07-01 |
20100167967 | WELLBORE TREATMENT WITH HYDROCARBON-RESPONSIVE FLUID CONTAINING OLIGOMERIC VISCOELASTIC SURFACTANT - A treatment of a subterranean formation which contains a hydrocarbon-bearing zone, is carried out using a hydrocarbon-responsive fluid thickened with an oligomeric surfactant consisting of from 2 to 8_linked surfactant monomer subunits. The process of treatment comprises
| 2010-07-01 |
20100167968 | LUBRICATING COMPOSITION WITH AN ADAPTABLE COEFFICIENT OF FRICTION, FOR A THREADED ELEMENT OF A COMPONENT OF A TUBULAR THREADED JOINT - A thin adhesive lubricating composition that can cover at least one thread and a screwing abutment of a threaded element of a component of a tubular threaded joint. The screwing abutment can bear against another abutment of another component of the tubular threaded joint in a terminal make up phase. The lubricating composition includes a matrix in which there is dispersed at least one braking additive selected to impart thereto, in addition to lubrication, a coefficient of friction to make it possible to obtain a torque on shoulder resistance value at least equal to a threshold value. | 2010-07-01 |
20100167969 | MARINE LUBRICANT FOR FUEL OIL HAVING HIGH AND LOW SULPHUR CONTENTS - The present invention for a two-stroke marine engine, which can be used with both high-sulphur content fuel oils and low-sulphur content fuel oils. It relates to a cylinder lubricant having a BN determined according to the standard ASTM D-2896 greater than or equal to 40 milligrams of potash per gram of lubricant, comprising a lubricant base stock for marine engines and at least one overbased detergent based on alkali metals or alkaline-earth metals, characterized in that it also contains a quantity of 0.01% to 10% preferably 0.1% to 2% by weight relative to the total weight of the lubricant, of one or more (A) compounds chosen from the primary, secondary or tertiary monoalcohols the alkyl or alkylene chain of which is saturated or unsaturated, linear or branched and comprises at least 12 carbon atoms. This lubricant has a sufficient neutralization capacity vis-à-vis the sulphuric acid formed during the combustion of high-sulphur fuel oils, while limiting the formation of deposits during the use of low-sulphur fuel oils. | 2010-07-01 |
20100167970 | OIL SOLUBLE POLYMERS - The invention relates to a polymer comprising 50-100% by weight, with regard to the weight of the polymers, of repeating units, which are derived from one or more ethylenically unsaturated ester compounds of formula (I), in which R represents hydrogen or methyl; R | 2010-07-01 |
20100167971 | POROUS, DISSOLVABLE SOLID SUBSTRATE AND SURFACE RESIDENT INORGANIC PARTICULATE PERFUME COMPLEXES - The present invention relates to personal care compositions, especially those personal care compositions in the form of a personal care article that is a porous dissolvable solid substrate. The porous dissolvable solid substrate has a surface resident coating comprising an inorganic particulate perfume complex that can provide a consumer benefit. | 2010-07-01 |
20100167972 | CLEANING SOLUTION FOR SUBSTRATE FOR SEMICONDUCTOR DEVICE AND PROCESS FOR PRODUCING SUBSTRATE FOR SEMICONDUCTOR DEVICE - To provide a cleaning solution for a substrate for a semiconductor device which is excellent in the ability to remove particles, organic contaminants, metal contaminants and composite contaminants of an organic matter and a metal attached on a substrate surface, whereby the substrate surface can be highly cleaned, without being corroded. Particularly, to provide a cleaning solution which is excellent in the ability to clean low dielectric constant (Low-k) materials on which liquid is easily repelled due to hydrophobic and of which the ability to remove particles is poor. | 2010-07-01 |
20100167973 | CLEANING AND DISINFECTING AGENT - A detergent and disinfectant in which water-soluble permanganates are used in an alkaline solution in order to initiate the oxidation of organic substances and simultaneously a chemical oxidant, preferably a peroxodisulfate, is used which is capable of producing radical reactions with catalytic support by manganates originating from the supplied permanganate, which reactions produce the oxidation of organic substances. All components are present in powder form and a respective powder mixture can be dissolved rapidly and free from residues in water. It thus represents a universally applicable, highly effective detergent and disinfectant. | 2010-07-01 |
20100167974 | CLEANING COMPOSITIONS PACKAGED IN ETHOXYLATED POLYVINYLALCOHOL MATERIALS - Use of a film forming material comprising an ethoxylated poly(vinylalcohol) for the manufacturing of water-soluble packaging for a detergent composition or related material. | 2010-07-01 |
20100167975 | CLEANING FORMULATION FOR A DISH WASHER - A detergent formulation for machine dishwashing comprises:
| 2010-07-01 |
20100167976 | Composition - A solid zeolite free soluble water softening composition comprises an effervescent system including an organic acid and an alkali which react together upon dissolution in water. | 2010-07-01 |
20100167977 | CLOTHES WASHING PRODUCT - The invention relates to a clothes washing product. According to the invention, a solar ultraviolet, radiation filtering substance is added to the conventional composition of a clothes washing product, such as a softener, detergent (structured or non-structured liquid, powder or tablets), pre-wash products, stain removers, scale removers, whiteners or any other additive. Consequently, with each wash, the ultraviolet radiation filtering substance is deposited on the clothes, forming a barrier thereon that protects the wearer's skin from harmful radiation, the cumulative effects of which can be serious. | 2010-07-01 |
20100167978 | ALL SURFACE CLEANER PROTECTOR - A cleaning/protecting solution is provided comprising: a) 90-99.5% by weight of a solvent mixture comprising: i) 70-99% by weight water; and ii) 1%-30% by weight of a water-miscible alcohol; and b) 0.5-10% by weight of a fluorinated quaternary silane. In some embodiments, the cleaning solution additionally comprises: c) 0.1-5% by weight of a non-ionic surfactant. In some embodiments, the cleaning solution comprises no ionic surfactant. In some embodiments, the cleaning solution additionally comprises: d) 0.1-5% by weight of a non-fluorinated quaternary silane. | 2010-07-01 |
20100167979 | RHEUMATOID ARTHRITIS-PREVENTIVE AGENT FOR ORAL INTAKE - There is provided a rheumatoid arthritis inhibitor for oral intake that has an inhibitory effect on rheumatoid arthritis and is excellent in safety. The rheumatoid arthritis inhibitor for oral intake of the present invention contains, as an active component, a casein hydrolysate containing free amino acids and peptides obtained by hydrolyzing animal milk casein to have an average chain length of not longer than 2.1 in terms of the number of amino acid residues, or a mixture of free amino acids and peptides contained in the hydrolysate. | 2010-07-01 |
20100167980 | Prolyl Endopeptidase Inhibitors For Reducing or Preventing Neutrophilic Inflammation - Provided herein are methods for reducing or preventing neutrophilic inflammation in a subject comprising selecting a subject with or at risk for neutrophilic inflammation and administering to the subject an agent that inhibits the expression or activity of prolyl endopeptidase. Provided herein are also methods for treatment or prevention of diseases associated with neutrophilic inflammation. | 2010-07-01 |
20100167981 | Encapsidation of Heterologous Entities into Virus-Like Particles - Methods are provided for the utilization of bacterial cell-free extracts in the synthesis of high yields of virus like particles with encapsidated cargo. | 2010-07-01 |
20100167982 | BARRIER INTEGRITY IN HIV PATIENTS - The invention concerns a method for stimulating intestinal barrier integrity in a patient infected with HIV by administering to said patient composition comprising: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (ARA), and at least two distinct oligosaccharides. | 2010-07-01 |
20100167983 | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis - The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject. The subject invention also provides a package comprising glatiramer acetate, rasagiline or the pharmaceutically acceptable salt thereof and instructions for use of the together to alleviate a symptom of a form of multiple sclerosis in a subject. The subject invention further provides a pharmaceutical combination comprising separate dosage forms of an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, which combination is useful to alleviate a symptom of a form of multiple sclerosis in a subject. | 2010-07-01 |
20100167984 | Complex between human insulin and an amphiphilic polymer and use of this complex in the preparation of a fast-acting human insulin formulation - The invention relates to a complex between human insulin and an amphiphilic polymer comprising carboxyl functional groups, said amphiphilic polymer being chosen from functionalized polysaccharides predominantly composed of glycoside monomers bonded via glycoside bonds of (1,6) type which are functionalized by at least one tryptophan derivative. | 2010-07-01 |
20100167985 | ORAL INSULIN COMPOSITION AND METHODS OF MAKING AND USING THEREOF - A method of lowering blood glucose in a mammal includes orally administering a therapeutically effective amount of crystallized dextran microparticles and insulin to the mammal to lower blood glucose of the mammal. The composition may be a one phase or a structured multi-phase composition for controlled release of insulin. | 2010-07-01 |
20100167986 | Cholesteryl Ester Transfer Protein Inhibitors - Compounds of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), A | 2010-07-01 |
20100167987 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR HEALING WOUNDS - A pharmaceutical composition and method for inducing or accelerating a healing process of a skin wound are described. The pharmaceutical composition contains, as an active ingredient, a therapeutically effective amount of at least one agent for modulating PKC production and/or activation, and a pharmaceutically acceptable carrier. The method is effected by administering the composition to a wound. | 2010-07-01 |
20100167988 | ETHOXYPHENYLMETHYL INHIBITORS OF SGLT2 - The present invention relates to new ethoxyphenylmethyl modulators of SGLT2, pharmaceutical compositions thereof, and methods of use thereof. | 2010-07-01 |
20100167989 | ISOPROPOXYPHENYLMETHYL INHIBITORS OF SGLT2 - The present invention relates to new isopropoxyphenylmethyl inhibitors of SGLT2, pharmaceutical compositions thereof, and methods of use thereof. | 2010-07-01 |
20100167990 | Pharmaceutical Formulations Comprising an Insulin Derivative - The invention concerns a soluble pharmaceutical formulation comprising an insulin derivative wherein the formulation further comprises more than 4 zinc atoms per 6 molecules of the insulin derivative, and a citric acid monohydrate and/or a histidine compound used in an amount sufficient to increase the tendency of the insulin derivative to self-associate into dodecamers. The invention further comprises a process for preparing the soluble pharmaceutical formulation. | 2010-07-01 |
20100167991 | Polysaccharides comprising carboxyl functional groups substituted by a hydrophobic alcohol derivative - The invention relates to a polysaccharide comprising carboxyl functional groups, one at least of which is substituted by a derivative of a hydrophobic alcohol. The invention also relates to a pharmaceutical composition comprising one of the polysaccharides according to the invention and at least one active principle. It also relates to a pharmaceutical composition, wherein the active principle is chosen from the group consisting of proteins, glycoproteins, peptides and nonpeptide therapeutic molecules. The invention also relates to the use of the functionalized polysaccharides according to the invention in the preparation of pharmaceutical compositions as described above. | 2010-07-01 |
20100167992 | Phenyl Ester Side Chains to Increase Polymer Resorptivity - The present invention relates to polymers modified to increase their resorbability. In particular, the polymers of the invention have phenyl ester side chains which are good leaving groups and which thereby increase the resorption rate of the polymer relative to the same polymer, for example, bearing a comparable amount of an alkyl ester side chain. Such polymers are generally water insoluble, but when modified are able to solublize drugs and upon degradation and resorption, release those in a physiological environment in a controlled and/or sustained manner. | 2010-07-01 |
20100167993 | Compounds for Enhancing p21 Expression and Methods of Use Thereof - The present invention relates to a method for identifying a drug candidate for enhancing expression of p21ctpl/wafl in a human patient suffering from a medical condition that can be treated by enhancing expression of p21Cφl/wafl. The method includes (a) providing a cell line comprising a nucleic acid sequence that comprises a p21ctpl/wafl promoter operationally ligated to a reporter domain; (b) exposing the cell line to a compound; and (c) identifying a compound that induces expression of the reporter domain. The compound that induces expression of the reporter domain is a drug candidate for treating a medical condition that can be treated by enhancing expression of p21cipl/wafl. | 2010-07-01 |
20100167994 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY - Peptides and compounds are provided that function as EWS-FLI1 protein inhibitors. The peptides and compounds have utility in the treatment of Ewing's sarcoma family of tumors. Also provided are methods of preparing the compounds and assays for identifying inhibitors of EWS-FLI1 protein. | 2010-07-01 |
20100167995 | PEPTOID COMPOUNDS - The invention relates to new peptoid compounds of formula (I), as well as their use in the treatment of bacterial infections, such as those caused by vancomycin resistant microorganisms, and to compositions thereof. | 2010-07-01 |
20100167996 | 3-Ether and 3-Thioether Substituted Cyclosporin Derivatives For the Treatment and Prevention of Hepatitis C Infection - This invention relates to cyclosporin derivatives of general formula (I): | 2010-07-01 |
20100167997 | METHOD FOR STIMULATION COLLAGEN SYNTHESIS AND/OR KGF EXPRESSION - The present invention relates to a method for stimulating collagen synthesis and/or KGF expression, and more particularly, to a method for stimulating collagen synthesis and/or KGF expression using the AIMP | 2010-07-01 |
20100167998 | Growth-stimulating polypeptides for use in fish and crustaceans - The present invention is related with polypeptides which show an increased activity compared with tilapia growth hormone. These polypeptides are able to stimulate growth, survival and the quality of fish and crustaceans larvae. Also, they increase the defences against pathogens and stimulate parameters related with the immune system of aquatic organisms. The polypeptides encoding genes were cloned into a | 2010-07-01 |
20100167999 | INHIBITION OF THE TUMORIGENIC POTENTIAL OF TUMOR STEM CELLS BY LIF AND BMPS - The present disclosure includes methods and compositions for the treatment or prevention of diseases and disorders characterized by excessive or misregulated cellular proliferations, including methods for the treatment of tumors. The methods involve the use of pharmaceutical compositions comprising at least one agent selected from the group consisting of a LIF preparation, a BMP preparation, a BMPR signalling activator, and a LIFR signalling activator. The disclosure also includes LIF preparations, BMP preparations, BMPR signalling activator, and LIFR signalling activators, and methods for the identification of LIF preparations, BMP preparations, BMPR signalling activator, and LIFR signalling activators. The disclosure also includes pharmaceutical compositions comprising at least one agent selected from the group consisting of a LIF preparation, a BMP preparation, a BMPR signalling activator, and a LIFR signalling activator. | 2010-07-01 |
20100168000 | Octanoate-Reduced Human Albumin - The invention relates to the improvement of the transport properties of albumin which is produced on an industrial scale, e.g. via the Cohn process or by means of recombinant processes, and is mixed, during the production process, with substances that saturate the binding points on the albumin and thus affect the binding properties and transport properties of the final product. A special embodiment of the invention relates to pasteurized and then octanoate-reduced human albumin for therapeutic use, especially in a detoxification treatment of human plasma, e.g. for the intravenous treatment of acute or chronic liver diseases, and as a dialysate in extracorporeal liver dialysis with albumin in the molecular adsorbent recirculating system (MARS) or in single-pass dialysis. | 2010-07-01 |
20100168001 | Method for Preventing and/or Treating Articles or Media Contaminated With Bacteria of the Legionelle Genus - The present invention relates to peptides that are active against bacteria of the | 2010-07-01 |
20100168002 | THERAPEUTIC PEPTIDES - The present invention provides a ligand isolated from | 2010-07-01 |
20100168003 | Agent for Treating Polyglutamine Aggregation-Caused Disease or Suppressing Onset Thereof - The present invention discloses an agent for treating a polyglutamine aggregation-caused disease or suppressing its onset, which comprises, as an active ingredient, (1) (i) HGF protein, (ii) a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein, or a salt of either of them, or | 2010-07-01 |
20100168004 | METHODS AND COMPOSITIONS FOR THE SYNERGISTIC ACTIVATION OF LATENT HIV - The present invention provides methods and compositions useful for the elimination of latent HIV reservoirs that persist despite HAART. The methods and compositions overcome this latent barrier by inducing the replication of HIV in latently infected T cells while preventing the spread of the newly produced virions to uninfected cells by providing HAART simultaneously. Compositions of the invention comprise an activator of latent HIV expression, such as prostratin, and an inhibitor of histone deacetylase, such as TSA. A surprising finding of this invention is that the inhibitor of the histone deacetylase synergizes the effect of prostratin thus, allowing administering to a patient a lower, non-toxic dose of prostratin. | 2010-07-01 |
20100168005 | Pyridin-3-yl derivatives as immunomodulating agents - The invention relates to pyridin-3-yl derivatives of Formula (I) wherein R | 2010-07-01 |
20100168006 | IN-PLANT PRODUCTION OF DIMERIC AND/OR OLIGOMERIC (COMPRISING THREE OR MORE UNITS) FORMS OF HUMAN APO A-1 PROTEIN MUTEINS - The present invention encompasses a method for the production of Apolipoproteins in dimeric and/or oligomeric forms (comprising three or more units) of muteins of the human ApoA-1 protein in plant seeds, novel variants of these proteins having an increased stability and capacity to transport cholesterol compared to the native ApoA-1 protein, expression systems for the production thereof, plants transformed capable of producing said proteins in seeds in dimeric and/or oligomeric forms, and nutraceutical derivatives of these plants. | 2010-07-01 |
20100168007 | Systems and Methods for Applying Cross-Linked Mechanical Barriers - A delivery device applies a biocompatible and biodegradable barrier material to a tissue region, e.g., to seal a vascular puncture site. The material comprises two liquid components, which are pre-packaged in individual dispensers. Upon mixing, the liquid components cross-link to create a barrier matrix. A holder attaches to the delivery device. The holder mutually supports the first and second dispensers while the protein solution and polymer solution are conveyed from the dispensers into a fluid delivery channel. The protein and polymer solutions mix as a result of flow through the channel. | 2010-07-01 |
20100168008 | METHOD OF USE OF EPIREGULIN PROTEIN AND NUCLEIC ACID ENCODING THE SAME IN INFLAMMATORY CONDITIONS - The present invention relates to nucleotide and protein sequences of epiregulin and epiregulin like proteins and nucleotides and methods employing them as a drug response marker in inflammatory conditions. The invention also provides epiregulin protein for treatment of inflammatory conditions like psoriasis and rheumatoid arthritis alone or in combination with one or more anti-inflammatory compounds. | 2010-07-01 |
20100168009 | PHa1B TOXIN, cDNA of Pha1B TOXIN GENE, PHARMACEUTICAL COMPOSITION CONTAINING PHa1B TOXIN, PROCESS AND PRODUCT - Methods and compositions for blocking calcium channels with a spider toxin from | 2010-07-01 |
20100168010 | COMPOSITIONS AND METHODS OF MODULATING CELL GROWTH AND MOTILITY - A method of modulating cell growth and motility in subject includes administering to a cell expressing GTPase an amount of an ARHGAP4 regulating agent effective to regulate the growth and motility of the cell. | 2010-07-01 |
20100168011 | Pharmaceutical Formulations and Methods for Making the Same - In certain embodiments, the invention relates to pre-lyophilization formulations, lyophilized compositions, reconstituted formulations, kits comprising the same, and methods for preparing, storing and using the same. | 2010-07-01 |
20100168012 | HUMAN CANCER THERAPY USING ENGINEERED MATRIX METALLOPROTEINASE-ACTIVATED ANTHRAX LETHAL TOXIN THAT TARGETS TUMOR VASCULATUTURE - The present invention provides methods for inhibiting tumor associated angiogenesis by administering a mutant protective antigen protein comprising a matrix metalloproteinase-recognized cleavage site in place of the native protective antigen furin-recognized site in combination with a lethal factor polypeptide comprising a protective antigen binding site. Upon cleavage of the mutant protective antigen by a matrix metalloproteinase, the lethal factor polypeptide is translocated into cancer and endothelial cells and inhibits tumor associated angiogenesis. | 2010-07-01 |
20100168013 | Neuromedin and FN-38 Peptides for Treating Psychiatric Diseases - Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an NMX peptide, an FNX peptide, or an NMX receptor agonist, or analogs or derivatives thereof, to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders. | 2010-07-01 |
20100168014 | Screening method - The present inventors have found that relaxin-3 has a feeding-stimulating activity, a body weight increasing activity, and fat weight increasing activity by intracerebroventricularly administering relaxin-3 to rats and observing the amount of feeding, body weight and fat weight, and so on after the administration. According to the present invention, a polypeptide having useful effects in stimulating feeding, increasing body weight, and fattening; a therapeutic agent containing said polypeptide; a method of screening for a compound, a substance, or a salt thereof which activates or suppresses a receptor of said polypeptide; a kit for said screening; and an agent which comprises a substance which inhibits expression of said polypeptide, such as a feeding-surpressing agent, a therapeutic agent for the treatment of obesity, and a therapeutic agent for the treatment of diabetes. | 2010-07-01 |
20100168015 | PEPTIDES WITH CAPACITY FOR BINDING WITH INTERLEUKINE 10 (IL-10) - The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions. | 2010-07-01 |
20100168016 | DIAGNOSIS AND TREATMENT OF DISEASES CAUSED BY MISFOLDED PROTEINS - In certain aspects, the disclosure relates to methods and compositions for diagnosing and treating diseases caused by misfolded proteins that comprise monitoring ANKRD 16 expression and altering the activity of ANKRD 16 protein. In certain embodiments, the diseases are neurodegenerative diseases. In certain embodiments, the diseases are proteopathies. In certain embodiments, the disease is reduced fertility. Methods for identifying agents that protect against cell death are also provided. | 2010-07-01 |
20100168017 | FUNCTIONAL SERUM PROTEIN PRODUCT FOR USE IN INFANT FOOD AND THERAPEUTIC COMPOSITIONS AND METHODS FOR THE PREPARATION THEREOF - The invention relates to a serum protein product, suitable as an ingredient for foods and therapeutic compositions, in particular infant and baby foods. The invention also provides a method for the preparation of the serum protein product, based on micro filtration of milk. The invention provides a method for the preparation of a serum protein product, comprising the preparation of a permeate through micro filtration of cow's milk at a temperature of between 10 and 20° C. utilizing a membrane having a pore size of between 0.3 and 0.5 μm. | 2010-07-01 |
20100168018 | FACTOR VIII FORMULATIONS - A Factor VIII (FVIII) composition formulated such that NaCl is not present in the final formulation or is present in trace amounts, which allows for a concomitant reduction in the lyophilization cycle time and increased stability of the lyophilized FVIII. | 2010-07-01 |
20100168019 | PEPTIDE CONJUGATED ANTI-CANCER PRODRUGS - The present invention relates to prodrug molecules comprising conjugates of an antiproliferative drug, a protease specific cleavable peptide, and, optionally, a targeting peptide, with the prodrugs being substantially inactive prior to degradation of the cleavable sequence by proteolytic enzymes abundant within or in close proximity to the target cancer cell. Also, pharmaceutical compositions of the conjugates and the use of these compositions for treatment of cancer are disclosed. | 2010-07-01 |
20100168020 | STABILIZED RECEPTOR POLYPEPTIDES AND USES THEREOF - The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided. | 2010-07-01 |
20100168021 | UROCORTIN PROTEINS AND USES THEREOF - A human urocortin-related peptide with significant sequence homology to the CRF neuropeptide family was identified. A mouse cDNA was isolated from whole brain poly (A+) RNA that encodes a predicted 38 amino acid peptide protein designated herein as urocortin II. Both human URP and mouse Ucn II are structurally related to the other known mammalian family members, CRF and urocortin (Ucn). These peptides are involved in the regulation of the hypothalamic-pituitary-adrenal axis under basal and stress conditions, suggesting a similar role for URP and Ucn IL Synthesized Ucn-II and URP peptide binds with higher affinity to CRF-R2 than to CRF-R1 Ucn II and human URP appear to be involved in the regulation of body temperature and appetite and may play a role in other stress related phenomenon. These findings identify Ucn II and human URP as a new members of the CRF family of neuropeptides, which are expressed centrally and bind to CRF-R2. | 2010-07-01 |
20100168022 | Use of In-Vitro Culture to Design or Test Personalized Treatment Regimens - Provided herein are methods of assessing responsiveness to an agent, methods of customizing treatments, methods of screening agents, and methods of treatment. Also provided are systems and kits for carrying out the methods contemplated herein. An exemplary aspect includes a method of assessing whether a subject having a condition, disorder, dysfunction, or disease would respond to treatment with an agent. The method comprises obtaining a stem cell sample from the subject; culturing the sample; exposing the sample to an agent; evaluating the sample in the presence of and in the absence of the agent to create a sample profile; and comparing the sample profile to a reference profile indicative of responsiveness to the agent. The similarity between the sample profile and the reference profile indicates the subject's responsiveness to the agent. | 2010-07-01 |
20100168023 | Injectable Botulinum Toxin Formulations - This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions contemplated by the invention exhibit one or more advantages over conventional botulinum toxin formulations, including reduced antigenicity, a reduced tendency to undergo unwanted localized diffusion following injection, increased duration of clinical efficacy or enhanced potency relative, faster onset of clinical efficacy, and/or improved stability. | 2010-07-01 |
20100168024 | DIRECT UTILIZATION OF PLASMA PROTEINS FOR THE IN VIVO ASSEMBLY OF PROTEIN-DRUG/IMAGING AGENT CONJUGATES, NANOCARRIERS AND COATINGS FOR BIOMATERIALS - The present invention includes compositions and methods for making and using a drug conjugated to a peptide or protein that binds specifically to a ligand in vivo, wherein the conjugate binds to its ligand in vivo and increases the half-life of the drug. | 2010-07-01 |
20100168025 | Stroke-generated angiogenesis enhancers and uses thereof - The present invention is drawn to methods of stimulating or enhancing angiogenesis in a patient comprising, administering to said patient a therapeutically effective amount of an endorepellin protein, wherein said endorepellin protein has an amino acid sequence of domain V of perlecan or fragments or derivatives, analogs thereof; and stimulating or enhancing generation of blood vessels. The present invention is drawn to compositions for enhancing angiogenesis. | 2010-07-01 |
20100168026 | INSULIN SECRETION INDUCER, AND ACCELERATOR FOR INCREASING THE NUMBER OF PANCREATIC BETA-CELLS - Disclosed are: an insulin secretion inducer; an insulin secretion-inducing composition; a process for the production of the composition; an accelerator for increasing the number of pancreatic β-cells; a composition for increasing the number of pancreatic β-cells; a process for the production of the composition; and a viral vector for gene therapy. The insulin secretion inducer or the accelerator for increasing the number of pancreatic β-cells comprises a polypeptide having an amino acid sequence encoded by DNA that is known to encode a membrane protein Tm4sf20 (transmembrane 4 L six family member 20) or the like or a fragment of the polypeptide as an active ingredient. | 2010-07-01 |
20100168027 | BPC-1: A SECRETED BRAIN-SPECIFIC PROTEIN EXPRESSED AND SECRETED BY PROSTATE AND BLADDER CANCER CELLS - Described is a novel gene and its encoded secreted tumor antigen, termed BPC-1, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers which express BPC-1, particularly including prostate cancer and bladder cancer. In human normal tissues, BPC-1 is only expressed in certain tissues of the brain. However, BPC-1 is expressed at high levels in prostate cancer cells and is also expressed in bladder cancer cells. The structure of BPC-1 includes a signal sequence and a CUB domain. BPC-1 protein is secreted. Preliminary experimental evidence suggests that BPC-1 is directly involved in oncogenesis or maintenance of the transformed phenotype of cancer cells expressing BPC-1. BPC-1 also appears to bind specifically to a cellular protein expressed in prostate cancer cells and other cells. | 2010-07-01 |
20100168028 | COMPOSITIONS AND METHODS OF USING CRMP-1 AND ITS FRAGMENTS FOR TREATING CANCER - Active fragments of hcrmp1 that are capable of inhibiting cell proliferation, invasive activity, and metastasis of cancer and methods of using the same for treating cancer are disclosed. The method can also be used prior to, or in combination with, the administration a chemotherapy agent. Vectors capable of expressing an hcrmp1, variants of hcrmp1, fragments of hcrmp1 and/or variants of fragments of hcrmp1 are also disclosed. | 2010-07-01 |
20100168029 | METHODS FOR TREATING BONE TUMORS - The present invention provides methods of treating bone cancer, inducing differentiation of bone tumor cells, inhibiting bone tumor growth, inducing bone tumor regression or treating a hyperproliferative cell disorder by administering a pharmaceutically effective amount of a bone morphogenic protein or a nucleic acid encoding the bone morphogenic protein. | 2010-07-01 |
20100168030 | Methods and compositions for treatment of organophosphate-caused pathology - A method of treating an organophosphate toxin-caused cardiac abnormality is described which includes administering a pharmaceutical composition including a therapeutically effective amount of a chloride current modulator to an individual subject having a cardiac abnormality caused by intoxication with an organophosphate toxin. The chloride current modulator is effective to modulate a chloride conductance and thereby reduce a symptom or sign of an organophosphate toxin-caused cardiac abnormality, thus treating the toxin-caused cardiac abnormality. Optionally, included is administering a therapeutic agent to inhibit an organophosphate toxin-caused distortion of the action potential of myocytes, support restoration of usual intracellular ionic concentrations, and support an increase in cardiac contractility. A composition according to the invention is described which includes a chloride current modulator; and a therapeutic agent to inhibit an organophosphate toxin-induced distortion of the action potential of myocytes, support restoration of usual intracellular ionic concentrations, and support an increase in cardiac contractility. | 2010-07-01 |
20100168031 | Lat peptides and their use in assays for identifying immunosuppressants - The invention relates to novel peptides and their use in assays for identifying novel immunosuppressants. More particularly the present invention provides methods and compositions for identifying compounds that will modulate the interaction of protein tyrosine kinase substrates with their intracellular ligands, as well as between their intracellular ligands and other members of the signaling pathway. | 2010-07-01 |
20100168032 | Smart Pro-Drugs of Serine Protease Inhibitors - The present invention relates to prodrugs of protease inhibitors, such as inhibitors of the proteosome, DPP IV, FAPα and the like. These “pro-inhibitors” are activated, i.e., cleaved, by an “activated protease” to release an active inhibitor moiety in proximity to a “target protease”. The identity of activating protease and target protease can be the same (such as pro-inhibitors being referred to as “Target-Activated Smart Protease Inhibitors” or “TASPI”) or different (e.g., “Target-Directed Smart Protease Inhibitors” or “TDSPI”). After activation of the pro-inhibitor, the active inhibitor moiety can self-inactivate by, e.g., intramolecular-cyclization or cis-trans isomerization. | 2010-07-01 |
20100168033 | UNACYLATED GHRELIN AS THERAPEUTIC AGENT IN THE TREATMENT OF METABOLIC DISORDERS - An isolated polypeptide comprising any amino acid fragment of unacylated ghrelin or any analog thereof, wherein the polypeptide has an activity selected from the group consisting of a) decreasing blood glucose levels; b) increasing insulin secretion an/or sensitivity; c) binding to insulin-secreting cells; and d) promoting survival of insulin-secreting cells. As well as the use of the polypeptide in the treatment of a disorder associated with impaired glucose metabolism. | 2010-07-01 |
20100168034 | PEPTIDE HAVING CELL MEMBRANE PENETRATING ACTIVITY - The present invention provides a peptide having cell membrane penetrating activity, a transmembrane carrier comprising the peptide having cell membrane penetrating activity as an effective component, a transmembrane complex consisting of the peptide having cell membrane penetrating activity combined with a target substance, a transfection kit comprising the peptide having cell membrane penetrating activity and the target substance, use of the peptide having cell membrane penetrating activity for the manufacture of a transmembrane complex, use of the transmembrane complex for the manufacture of a medicament, and a method for delivering a target substance into cell interior which comprises administrating to a subject with a transmembrane complex consisting of the peptide having cell membrane penetrating activity combined with a target substance to induce transduction of the transmembrane complex into cell interior. The peptide having cell membrane penetrating activity of the present invention has a prominent penetrating efficiency as compared with the activities of prior TAT-derived peptides and so the peptide has applications on intracellular delivery in various research fields as well as on therapeutics of specific diseases where targeting of drugs is required at high efficiency. Accordingly, the peptide having cell membrane penetrating activity, the transmembrane complex consisting of the peptide combined with a target substance and the method for delivering a target substance into cell interior using the transmembrane complex of the present invention are very useful as drug delivery systems. | 2010-07-01 |
20100168035 | SUBCUTANEOUS IMPLANTS CONTAINING A DEGRADATION-RESISTANT POLYLACTIDE POLYMER - The present invention refers to compositions comprising a LH-RH-analogue and/or pharmaceutically acceptable salts thereof in a low-dose and a degradation-resistant polylactide suitable for the preparation of subcutaneous implants. Sterilisation of the polylactide via gamma-radiation as well as temperature stress result in a negligible decomposition of less than 1000 Dalton. | 2010-07-01 |
20100168036 | GROWTH FACTOR - The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer. | 2010-07-01 |
20100168037 | PEPTIDES COMPRISING AROMATIC D-AMINO ACIDS AND METHODS OF USE - Disclosed are D-peptides and libraries of D-peptides comprising aromatic D-amino acids. Also disclosed are methods for identifying small D-peptides comprising aromatic D-amino acids that bind to proteins of interest | 2010-07-01 |
20100168038 | USE OF COMPOUNDS IN COMBINATION WITH GAMMA-IRRADIATION FOR THE TREATMENT OF CANCER - TPP II (tripeptidyl peptidase inhibitors are useful in enhancing the efficacy of gamma-irradiation cancer therapy or increasing the in vivo gamma-irradiation susceptibility of tumour cells. Suitable compounds comprise tripeptide compounds of general formula R | 2010-07-01 |
20100168039 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions - Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described. | 2010-07-01 |
20100168040 | MUSCLE FATIGUE REMEDY - A muscle fatigue remedy that for persons with the symptoms of muscle pain attributed to strenuous exercise, lassitude in the arms and legs attributed to acute exercise, lower back pain and stiffness in the shoulder attributed to taking of a certain posture over a prolonged period of time, etc., relieves the symptoms and allows them to have a fulfilling life. There is provided a muscle fatigue remedy containing alanylglutamine or its salt as an active ingredient. | 2010-07-01 |
20100168041 | COMBINATION OF MONOSACCHARIDES AND DESQUAMATING AGENTS, AND USE THEREOF - The present invention relates to a composition, especially a cosmetic and/or dermatological composition, containing, in a physiologically acceptable medium, a combination of at least one monosaccharide chosen from mannose, rhamnose and a mixture thereof, and of at least one desquamating agent. The present invention also relates to the use of such a composition, and to a device containing it. | 2010-07-01 |
20100168042 | ACTIVE AGENT COMBINATIONS WITH INSECTICIDAL AND ACARICIDAL PROPERTIES - The invention relates to novel insecticidal active compound combinations comprising, firstly, cyclic ketoenols or other acaricidally active compounds and, secondly, further insecticidally active compounds from the group of the anthranilamides, which combinations are highly suitable for controlling animal pests, such as insects and unwanted acarids. | 2010-07-01 |
20100168043 | METHOD FOR THE PROTECTION OF TREES - The present invention provides a method for the prevention/treatment of hark beetle and/or wood borer infestation of trees comprising treatment of the tree with a composition comprising a macroyclic lactone. | 2010-07-01 |
20100168044 | SUPERPARAMAGNETIC NANOPARTICLE ENCAPSULATED WITH STIMULI RESPONSIVE POLYMER FOR DRUG DELIVERY - The current invention is a novel superparamagnetic site-targeting nanoparticle comprising superparamagnetic nanoparticles encapsulated with a smart polymer. The superparamagnetic site-targeting nanoparticle comprises a functionalized superparamagnetic core that is conjugated with a therapeutic agent and then encapsulated with a smart polymer. The smart polymer can be any polymer that exhibits a reversible conformational or physio-chemical change in response to an external stimulus or stimuli. | 2010-07-01 |
20100168045 | Novel Polyunsaturated Compounds, Method for Preparing Same and Compositions Containing the Same - The invention concerns novel polyunsaturated compounds of formula (I) wherein: R | 2010-07-01 |
20100168046 | METHODS OF USING [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF FOR TREATING INFECTIOUS DISEASES - Disclosed are methods of treating infectious diseases comprising administering to the animal, a therapeutically effective amount of a heterocyclic compound. The animal is a mammal, preferably a human or a rodent. | 2010-07-01 |
20100168047 | Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNA as anti-inflammatory therapeutics - The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines or inhibiting activation of NFKB by inhibiting expression of apoptosis-specific eIF-5A. | 2010-07-01 |
20100168048 | Method of Stabilizing S-Adenosyl-L-Methionine and Stabilized Composition - Provided are a process for producing a S-adenosyl-L-methionine-containing composition which is very excellent in a stability by adding at least ascorbic acids or salts thereof to a composition liquid containing S-adenosyl-L-methionine and then drying the above composition liquid or separating and drying a crystallized deposit obtained from the above composition liquid, a S-adenosyl-L-methionine-containing composition obtained by the above production process and a molding obtained from the above composition. | 2010-07-01 |
20100168049 | COMBINATION OF MONOSACCHARIDES AND ADENOSINE AND USE THEREOF - The present invention relates to a composition, especially a cosmetic and/or dermatological composition, containing, in a physiologically acceptable medium, a combination of at least one monosaccharide chosen from mannose, rhamnose and a mixture thereof, and of at least one additional compound chosen from adenosine, an analogue thereof and a mixture thereof. | 2010-07-01 |
20100168050 | COMPOUNDS HAVING ANTIANGIOGENIC ACTIVITY - The use of o-ATP as a pharmacological agent useful for the treatment of diseases in whose onset or progression angiogenesis is involved. | 2010-07-01 |
20100168051 | Altered Mitochondrial Activity in Diseases Resulting From Oxidative Stress - The present invention relates to the identification of a subject having or at risk of developing a disease resulting from oxidative stress in the body. The present invention also relates to the identification of a diabetic subject having or at risk of developing microvascular disease, kidney disease, and/or cardiovascular disease. | 2010-07-01 |
20100168052 | Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation - A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient. | 2010-07-01 |
20100168053 | ORAL DELIVERY SYSTEM FOR METHYLCOBALAMIN TO TREAT DISORDERS - A method of treating a disorder by lollipop administering methylcobalamin, with or without folinic acid by direct delivery to the trigeminal nerve. The disorders addressed are: a) attention deficit hyperactivity disorder (ADHD); b) anxiety, depression, stress and chronic stress; c) socialization problems, mood problems, behavior problems, memory problems; d) dyslexia, depth perception problems, color viewing problems, visual and auditory processing problems, light modulation problems, night vision problems; e) speech problems such as finding words, apraxia, and articulation problems, sleep regulation problems, eye or muscle movement problems; and f) chronic fatigue problems, digestion problems, sensitivity to chemicals, viral infection, inflammatory conditions such as rheumatoid arthritis, sciatica, and fibromyalgia, asthma, irritable bowel, colitis, tinnitus, migraines, nail biting, autoimmune problems. In some embodiments, the disorders that are particularly addressed are ADHD, anxiety, stress and chronic stress, and irritable bowel. A lollipop for treating a psychological or neuro-physiological disorder and method of making thereof. | 2010-07-01 |
20100168054 | Functionalized Beta 1,6 Glucosamine Disaccharides and Process for Their Preparation - The present invention relates to a novel process for the chemical synthesis of β-(1->6)-linked glucosamine disaccharides of the formula (1) and (intermediate) compounds relating to the process. According to further aspects the invention relates to compositions comprising the compounds and the use of the compounds in the synthesis of disaccharides and medicine. | 2010-07-01 |
20100168055 | COMBINATION OF MONOSACCHARIDE WITH C-GLYCOSIDE DERIVATIVE AND USE THEREOF - Composition, especially a cosmetic and/or dermatological composition, containing, in a physiologically acceptable medium, at least one of mannose, and rhamnose and at least one additional compound chosen from C-glycosides and C-glycoside derivatives. Use of such a composition, and also a device containing it. | 2010-07-01 |
20100168056 | DIETARY FIBER FORMULATION AND METHOD OF ADMINISTRATION - The invention provides dietary fiber formulation and related methods for its administration. In one embodiment, the invention provides a dietary fiber formulation comprising: partially-hydrolyzed guar gum (PHGG); and fructooligosaccharides (FOS), wherein the dietary fiber formulation exhibits a prebiotic potential greater than a prebiotic potential of PHGG and FOS individually. | 2010-07-01 |
20100168057 | FUNGAL GROWTH INHIBITOR - A very safe and useful agent for inhibiting fungal growth and the like are provided by the present invention. Specifically, the present invention provides (1) an agent for inhibiting fungal growth comprising hyaluronic acid or a salt thereof excluding a heavy metal salt as the active ingredient, and a method for inhibiting fungal growth, which comprises at least a step of allowing hyaluronic acid or a salt thereof excluding a heavy metal salt to contact with a fungus, (2) an agent for reinforcing activity of inhibiting fungal growth possessed by a cell, which comprises a DNA encoding a hyaluronic acid synthase as the active ingredient, (3) a method for reinforcing activity of inhibiting fungal growth of a cell, which comprises at least a step of transfecting a DNA encoding a hyaluronic acid synthase into the cell, and (4) a method for inhibiting fungal growth, which comprises at least a step of allowing a cell transfected with a DNA encoding a hyaluronic acid synthase to contact with a fungus. | 2010-07-01 |
20100168058 | NOVEL ANTAGONISTS OF THE TOLL-LIKE RECEPTOR 4 - The present invention relates to a novel antagonist of the Toll-like receptor 4 (TLR-4). More specifically, the present invention relates to a lipopolysaccharide (LPS) isolated from the bacterium | 2010-07-01 |
20100168059 | HYALURONIC ACID NUTRITIONAL SUPPLEMENTS AND METHODS OF USING THE SAME - Hyaluronic acid nutritional supplements and methods of using the same. In at least one embodiment of a nutritional supplement of the present disclosure, the nutritional supplement comprises a quantity of a hyaluronic acid, or a salt or digest thereof, and a food acceptable carrier. | 2010-07-01 |
20100168060 | SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF - Salts of benzimidazolyl pyridyl ethers are provided, particularly salts of {1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl}-(4-trifluoromethyl-phenyl)amine. Compositions and formulations including such salts and surfactants as well as methods of preparing such compositions and formulations are provided. | 2010-07-01 |
20100168061 | METHOD FOR PREPARING ENZYMATICALLY HIGHLY BRANCHED-AMYLOSE AND AMYLOPECTIN CLUSTER - The present invention relates to a method for preparing enzymatically highly branched-amylose and amylopectin cluster. Alpha-glucanotransferase or branching enzyme hydrolyzes the linkage of the segment between amylopectin clusters in starch, producing amylopectin cluster, and simultaneously branching enzyme attaches the branched side-chain to amylose, producing branched amylose, and subsequently treating the amylopectin cluster or branched amylose with maltogenic amylase for cleaving long side chain into short side chain and for transferring glucose to the side chain, generating highly branched amylopectin cluster, highly branched amylose or branched oligosaccharide from starch effectively. | 2010-07-01 |
20100168062 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors - The present invention relates to quinoxaline compound of the formula (I): | 2010-07-01 |
20100168063 | BICYCLIC PYRIMIDINONES AND USES THEREOF - The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compound of Formula I is also provided. | 2010-07-01 |